Genetic Testing for Clinical Trials by SignatureDx
Our dedicated clinical trial team has the expertise and flexibility to help you determine cohort inclusion with the fastest available turn-around time
- Industry-leading 2 business day turnaround time available
- Unrivaled service and support
- Dedicated project manager and lab support team
- Direct guidance and assistance throughout the process
- Quick turn-around on quotes and contracts
Testing services include 100% of tier 1 alleles as classified by CAP including specific identification of CYP2D6 allele duplications.
- CLIA certified
- HIPAA Compliant
- Results can be provided via email, FTP, or SignatureDx's own delivery platform for instant access
Our core test menu includes depth into the alleles for:
In addition to the alleles above, we’re proud to offer LDTs and can custom build assays to fit the needs of your trial.
Precision medicine is the future for drug development
SignatureDx provides genotyping and phenotyping for pharmaceutical companies and CROs to support clinical trials for therapies that are dependent on the CYP450 enzymes for their metabolization. Our clinical trial testing helps your trial avoid drug-gene interactions to ensure patient safety, allowing for healthy patient cohorts that can safely metabolize the therapy. Our team has over 20 years of experience providing genetic testing, guiding clinical trials, developing assays, and designing research studies. We know how important it is to provide results quickly and accurately to keep trials moving forward while minimizing costs. SignatureDx offers best-in-class service and support with turnaround times that meet even the most demanding project needs.
We provide support for all phases of your clinical trial to help you safely determine patient eligibility and stratification.
Meet your personal clinical trial management team
Annie Shaw, Lab Supervisor
Annie has over 13 years’ experience managing clinical laboratories. Her responsibilities include processing tests, data analytics, and lab quality control. Annie previously worked at the Magee Womens Research Institute, leading execution on high-profile genetic testing projects and working directly with Dr. Peters to conduct and publish research.
Dr. Dave Peters, PhD, Chief Science Officer
Dr. David Peters has over three decades of experience genetic testing, conducting research studies, and working on clinical trials. Dr. Peters has been a leader and innovator in genetics since he took a position at the University of Pittsburgh in 1995. Dr. Peters continues to drive innovation at the University of Pittsburgh, the Magee Womens Research Institute, and as the Chief Science Officer at SignatureDx.
Dan Doherty, Lead Clinical Trial Project Manager
Dan has managed hundreds of genetics-related clinical trials since 2006, previously working with Genelex and Invitae. Dan brings a depth of knowledge in clinical phenotyping, drug/gene interactions, drug/drug interactions at the enzyme level, and has supported both patients and physicians in the rare disease space for years.
Phone: (206) 384-6357